{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:09:12Z","timestamp":1772892552336,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40121-019-00268-3","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T10:55:51Z","timestamp":1571655351000},"page":"627-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It\u2019s Complicated"],"prefix":"10.1007","volume":"8","author":[{"given":"Jessica K.","family":"Ortwine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan J.","family":"Zasowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Pogue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Hanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M.","family":"Casapao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Mynatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"issue":"1","key":"268_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398.","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"268_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1592\/phco.19.4.257.30933","volume":"19","author":"CM Karam","year":"1999","unstructured":"Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy. 1999;19(3):257\u201366.","journal-title":"Pharmacotherapy."},{"issue":"5","key":"268_CR3","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"268_CR4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u201355.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"268_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/cid\/ciu398","volume":"59","author":"TP Lodise","year":"2014","unstructured":"Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59(5):666\u201375.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"268_CR6","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1128\/AAC.03970-14","volume":"59","author":"AM Casapao","year":"2015","unstructured":"Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother. 2015;59(6):2978\u201385.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"268_CR7","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"268_CR8","doi-asserted-by":"publisher","first-page":"e01684-e17","DOI":"10.1128\/AAC.01684-17","volume":"62","author":"EJ Zasowski","year":"2017","unstructured":"Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, et al. Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin. Antimicrob Agents Chemother. 2017;62(1):e01684-e17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"268_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/AAC.01653-13","volume":"58","author":"MN Neely","year":"2014","unstructured":"Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"268_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/524667","volume":"46","author":"A Soriano","year":"2008","unstructured":"Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193\u2013200.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"268_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijantimicag.2012.10.015","volume":"41","author":"S Zelenitsky","year":"2013","unstructured":"Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013;41(3):255\u201360.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"268_CR12","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1128\/JCM.00448-13","volume":"51","author":"MJ Rybak","year":"2013","unstructured":"Rybak MJ, Vidaillac C, Sader HS, Rhomberg PR, Salimnia H, Briski LE, et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol. 2013;51(7):2077\u201381.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"268_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cmi.2017.06.017","volume":"24","author":"R Diaz","year":"2018","unstructured":"Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gato B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections\u2014a systematic review and meta-analysis. Clin Microbiol Infect. 2018;24(2):97\u2013104.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"268_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/phar.1531","volume":"35","author":"ED Adane","year":"2015","unstructured":"Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35(2):127\u201339.","journal-title":"Pharmacotherapy."},{"issue":"5","key":"268_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/00007691-199410000-00013","volume":"16","author":"MP Ducharme","year":"1994","unstructured":"Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994;16(5):513\u20138.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"268_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s002280050524","volume":"54","author":"LA Bauer","year":"1998","unstructured":"Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54(8):621\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"268_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1128\/AAC.21.4.575","volume":"21","author":"RA Blouin","year":"1982","unstructured":"Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21(4):575\u201380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"268_CR18","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2146\/ajhp110324","volume":"69","author":"DC Reynolds","year":"2012","unstructured":"Reynolds DC, Waite LH, Alexander DP, ReRyke CA. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm. 2012;69(11):944\u201350.","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"268_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2146\/ajhp100410","volume":"68","author":"JV Leong","year":"2011","unstructured":"Leong JV, Boro MS, Winter M. Determining vancomycin clearance in an overweight and obese population. Am J Health Syst Pharm. 2011;68(7):599\u2013603.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"268_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","volume":"38","author":"PA Moise","year":"2016","unstructured":"Moise PA, Culshaw DL, Wong-Beringer A, Bensman J, Lamp KC, Smith WJ, et al. Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC\u2009>\u20091\u00a0mg\/L: a multicenter evaluation. Clin Ther. 2016;38(1):16\u201330.","journal-title":"Clin Ther."},{"issue":"2","key":"268_CR21","doi-asserted-by":"publisher","first-page":"e01445-17","DOI":"10.1128\/AAC.01554-17","volume":"62","author":"J Truong","year":"2018","unstructured":"Truong J, Veillette JJ, Forland SC. Outcomes of vancomycin plus a beta-lactam versus vancomycin only for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2018;62(2):e01445-17.","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"268_CR22","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1128\/AAC.00227-16","volume":"60","author":"KC Claeys","year":"2016","unstructured":"Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, et al. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016;60(10):5841\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"268_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jiac.2017.11.002","volume":"24","author":"M \u0160\u00edma","year":"2018","unstructured":"\u0160\u00edma M, Hartinger J, Cik\u00e1nkov\u00e1 T, Slana\u0159 O. Importance of vancomycin loading doses in intermittent infusion regimens. J Infect Chemother. 2018;24(4):247\u201350.","journal-title":"J Infect Chemother."},{"issue":"8","key":"268_CR24","doi-asserted-by":"publisher","first-page":"e00280-17","DOI":"10.1128\/AAC.00280-17","volume":"61","author":"O \u00c1lvarez","year":"2017","unstructured":"\u00c1lvarez O, Plaza-Plaza JC, Ramirez M, Peralta A, Amador CA, Amador R. Pharmacokinetic assessment of vancomycin loading dose in critically ill patients. Antimicrob Agents Chemother. 2017;61(8):e00280-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"268_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1445-5994.2011.02459.x","volume":"42","author":"J Truong","year":"2012","unstructured":"Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J. 2012;42(1):23\u20139.","journal-title":"Intern Med J."},{"issue":"2","key":"268_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/1120009X.2017.1389807","volume":"30","author":"JL Wesolek","year":"2018","unstructured":"Wesolek JL, McNorton K, Delgado G Jr, Giuliano CA. Effect of vancomycin initial dosing on time to systemic inflammatory response syndrome resolution in patients with methicillin-resistant Staphylococcus aureus bacteremia. J Chemother. 2018;30(2):101\u20136.","journal-title":"J Chemother"},{"issue":"6","key":"268_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/acem.12934","volume":"23","author":"JM Rosini","year":"2016","unstructured":"Rosini JM, Davis JJ, Muenzer J, Levine BJ, Papas MA, Comer D, et al. High single-dose vancomycin loading is not associated with increased nephrotoxicity in emergency department sepsis patients. Acad Emerg Med. 2016;23(6):744\u20136.","journal-title":"Acad Emerg Med"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00268-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-019-00268-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00268-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:26:42Z","timestamp":1715668002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-019-00268-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["268"],"URL":"https:\/\/doi.org\/10.1007\/s40121-019-00268-3","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}